Sullivan
Microsoft has discontinued support for Internet Explorer. To access the Sullivan website, please install a modern browser like Microsoft Edge or Google Chrome.

People

Biotech Focused On Developing Non-Opioid Therapeutics to Alleviate Pain Announced IPO

Sullivan was issuer's counsel for Chromocell Therapeutics Corporation, a clinical-stage biotech company focused on developing and commercializing new, non-opioid therapeutics to alleviate pain, in their $6.6 million initial public offering of common stock.

The Sullivan team was led by David Danovitch, director of the firm’s Corporate Department, with partners Charles E. Chambers Jr., Aaron Schleicher and associate Brian Hurley. Sullivan has developed a strength in working with entrepreneurial biotech and tech companies in the U.S. and in Israel.

David E. Danovitch, Charles E. Chambers Jr. and Brian P. Hurley

Artificial Intelligence Company Advised in Growth Financing

Sullivan represented Impact Analytics Inc. in its $5.5 million growth financing round led by Argentum Capital Partners. The company unites artificial intelligence with human validation that brings machine learning to the forefront of data-driven business decisions.

Lewis N. Segall and Johanna Colpritt

Young businesswoman looking at smartphone in spaceship like corridor

People

People